Abstract:Development of dry powder aerosol delivery system involves powder production, formulation, dispersion, delivery, and deposition of the powder aerosol in the airways. Insufficiency of conventional powder production by crystallization and milling has led to development of alternative techniques. Over the last decade, performance of powder formulations has been improved significantly through the use of engineered drug particles and excipient systems which are (i) of low aerodynamic diameters (being porous or of low particle density), and/or (ii) less cohesive and adhesive (via corrugated surfaces, low bulk density, reduced surface energy and particle interaction, hydrophobic additives, and fine carrier particles). Early insights into particle forces and surface energy that help explain the improvement have been provided by analytical techniques such as the atomic force microscopy (AFM) and inverse gas chromatography (IGC). Relative humidity is critical to the performance of dry powder inhaler (DPI) products via capillary force and electrostatic interaction. Electrostatic charge of different particle size fractions of an aerosol can now be measured using a modified electrical low-pressure impactor (ELPI). Compared with powders, much less work has been done on the inhaler devices at the fundamental level. Most recently, computational fluid dynamics has been applied to understand how the inhaler design (such as mouthpiece, grid structure, air inlet) affects powder dispersion. The USP throat is known to under-represent the oropharyngeal deposition of DPI aerosols. Studies using magnetic resonance imaging (MRI) model casts have been undertaken to explain the inter- and intra- subject variation in oropharyngeal deposition. Most of the lung deposition studies performed on commercial products did not allow a thorough understanding of the determinants affecting in vivo lung deposition. A more systematic approach would be necessary to build a useful database on the dependence of lung deposition on the breathing parameters, inhaler design, and powder formulation properties.

Design, development, and technical considerations for dry powder inhaler devices

Formulation and Evaluation of Dry Powder Inhaler

Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies

[A Novel Pulmonary Delivery System--dry Powder Inhalers].

Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations

Dry Powder Inhalers: From Bench to Bedside

Focusing on powder processing in dry powder inhalation product development, manufacturing and performance

Engineering the right formulation for enhanced drug delivery

Progress on Dry Powder Inhalers

A Quality by Design Framework for Capsule-Based Dry Powder Inhalers

Combining experimental and computational techniques to understand and improve dry powder inhalers

Recent developments in the computational simulation of dry powder inhalers

Evaluating dry powder inhalers: From in vitro studies to mobile health technologies

Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives

Surface modification strategies for high-dose dry powder inhalers

Dry powder inhalation, part 2: the present and future

Dry Powder Aerosol Delivery Systems: Current and Future Research Directions

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems

The Formulation Factors of Influencing the Aerosolizing and Deposition Properties of Dry Powder Inhalation

Dosing challenges in respiratory therapies

Surface Analytical Techniques in Solid-State Particle Characterization for Predicting Performance in Dry Powder Inhalers